Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Swiss Re AG ( (CH:SREN) ) has issued an update.
Swiss Re’s recent study highlights the potential impact of GLP-1 medications on reducing mortality rates in the USA and UK by 2045, assuming widespread use and lifestyle changes. The study emphasizes the importance of lifestyle modifications alongside medication use to achieve significant mortality reductions, with implications for insurers in risk assessment and benefit claims development.
The most recent analyst rating on (CH:SREN) stock is a Buy with a CHF158.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
More about Swiss Re AG
The Swiss Re Group is a leading global provider of reinsurance, insurance, and other insurance-based risk transfer solutions, aiming to enhance global resilience. Founded in 1863 and headquartered in Zurich, Swiss Re operates through a network of approximately 70 offices worldwide, focusing on managing risks ranging from natural disasters to cybercrime.
Average Trading Volume: 600,384
Technical Sentiment Signal: Buy
Current Market Cap: CHF38.63B
Find detailed analytics on SREN stock on TipRanks’ Stock Analysis page.